Sugi Predict

Sugi Predict / Compounds / SCHEMBL3485872

SCHEMBL3485872

SCHEMBL3485872

CC(C)CNC(=O)CN1CCC(N(C(C)C)S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CACNA1B Q00975 10/20 0.47
▸ GAA P10253 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ LMNA P02545 3/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ UBE2M P61081 3/20 0.45
▸ DCUN1D1 Q96GG9 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ CACNA1C Q13936 1/20 0.44
▸ KMT2A Q03164 1/20 0.43
▸ NR1I2 O75469 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ RORC P51449 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485983 0.91 UBE2M (0.48) CACNA1BGAAHPGDLMNASMN1; SMN2
SCHEMBL3485141 0.87 POLB (0.49) CACNA1BLMNASMN1; SMN2UBE2MDCUN1D1
SCHEMBL13002406 0.86 CACNA1B (0.51) CACNA1BGAAHPGDLMNASMN1; SMN2
SCHEMBL3485159 0.85 CACNA1B (0.50) CACNA1BGAAHPGDCACNA1CKMT2A
SCHEMBL3485824 0.85 ALDH1A1 (0.52) CACNA1BLMNASMN1; SMN2UBE2MDCUN1D1
SCHEMBL3485265 0.85 ALDH1A1 (0.47) CACNA1BGAAHPGDLMNASMN1; SMN2
SCHEMBL3766572 0.85 LMNA (0.61) CACNA1BGAALMNASMN1; SMN2ALDH1A1
SCHEMBL3485918 0.85 TSHR (0.56) CACNA1BLMNASMN1; SMN2UBE2MDCUN1D1
SCHEMBL3485688 0.84 ALDH1A1 (0.50) CACNA1BGAALMNASMN1; SMN2UBE2M
SCHEMBL3486183 0.84 LMNA (0.48) CACNA1BGAALMNASMN1; SMN2UBE2M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 — — US claimed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 — — US claimed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 — — US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 — — US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 — — WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B CACNA1B 3/4885GAA 1863/4885HPGD 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.